Finding SKYLIGHT for all: fezolinetant efficacy for vasomotor symptoms in subpopulations

This publication has 13 references indexed in Scilit:

• Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study
  The Lancet, 2023
• The 2022 hormone therapy position statement of The North American Menopause Society
  Menopause, 2022
• Obesity, smoking, and risk of vasomotor menopausal symptoms: a pooled analysis of eight cohort studies
  American Journal of Obstetrics and Gynecology, 2020
• The menopause transition and women's health at midlife: a progress report from the Study of Women's Health Across the Nation (SWAN)
  Menopause, 2019
• Risk factors for hot flashes among women undergoing the menopausal transition
  Menopause, 2015
• Duration of Menopausal Vasomotor Symptoms Over the Menopause Transition
  JAMA Internal Medicine, 2015
• Low-dose paroxetine 7.5 mg for menopausal vasomotor symptoms
  Menopause, 2013
• Efficacy of Escitalopram for Hot Flashes in Healthy Menopausal Women
  JAMA, 2011
• Persistent Hot Flushes in Older Postmenopausal Women
  Archives of internal medicine (1960), 2008
• Hot Flashes in the Late Reproductive Years: Risk Factors for African American and Caucasian Women
  Journal of Women's Health & Gender-Based Medicine, 2001